Erin Feeney's Contact Details

Erin Feeney's Company Details

4D Path

, , • 10 - 19 Employees
Other

Just because you can't see something, doesn't mean it's not there. 4D Path's patented precision oncology platform is designed to unveil previously hidden data to instantly provide biomarker profiling and stratification directly from H&E whole slide biopsy/resection images only. 4D Path's cloud-based, quantitative approach is intended to eliminate the need for additional molecular tests (e.g., immunohistochemistry, FISH, RNA-Seq, NGS), accelerating complete, actionable and objective insight leading to expedited and democratized precision medicine. 4D Path's quantitative approach is designed to provide clinical solutions in both companion diagnostics and translational medicine without compromising the current standard of care to reduce the cost, time and complexity of patient care and management, and clinical trials. Our patented methods and integrated platform combine universal physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints in order to inform treatment selection and stratify patients accordingly. The U.S. Food & Drug Administration (FDA) has granted 4D Path Breakthrough Device Designation for our first software-as-a-medical-device solution, the 4D Q-plasia OncoReader Breast, which demonstrates promise of significant improvements over the existing standard of care by providing histopathologists with an adjunct technology to improve diagnostic accuracy of breast cancer features (e.g., its invasiveness, grades, etc.) solely from digitized histopathology images obtained via biopsies or resections.